DK1983990T3 - Allosteriske A3-adenosin-receptormodulatorer - Google Patents

Allosteriske A3-adenosin-receptormodulatorer

Info

Publication number
DK1983990T3
DK1983990T3 DK07763034.1T DK07763034T DK1983990T3 DK 1983990 T3 DK1983990 T3 DK 1983990T3 DK 07763034 T DK07763034 T DK 07763034T DK 1983990 T3 DK1983990 T3 DK 1983990T3
Authority
DK
Denmark
Prior art keywords
adenosine receptor
a3rm
a3ar
allosteric
subject
Prior art date
Application number
DK07763034.1T
Other languages
English (en)
Inventor
Johannes Brussee
Zhan-Guo Gao
Kenneth Jacobson
Aniko Goblyos
Adriaan P Ijzerman
Original Assignee
Us Gov Health & Human Serv
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Univ Leiden filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK1983990T3 publication Critical patent/DK1983990T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
DK07763034.1T 2006-01-26 2007-01-25 Allosteriske A3-adenosin-receptormodulatorer DK1983990T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76214106P 2006-01-26 2006-01-26
PCT/US2007/001930 WO2007089507A1 (en) 2006-01-26 2007-01-25 A3 adenosine receptor allosteric modulators

Publications (1)

Publication Number Publication Date
DK1983990T3 true DK1983990T3 (da) 2011-07-11

Family

ID=38116104

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07763034.1T DK1983990T3 (da) 2006-01-26 2007-01-25 Allosteriske A3-adenosin-receptormodulatorer

Country Status (10)

Country Link
US (2) US8420664B2 (da)
EP (1) EP1983990B1 (da)
JP (2) JP5414277B2 (da)
KR (1) KR101383228B1 (da)
CN (1) CN101410114B (da)
AT (1) ATE502640T1 (da)
DE (1) DE602007013359D1 (da)
DK (1) DK1983990T3 (da)
ES (1) ES2360632T3 (da)
WO (1) WO2007089507A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
DK1983990T3 (da) 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2013211E (pt) 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
WO2008000743A2 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2010508835A (ja) * 2006-11-10 2010-03-25 ノバルティス アーゲー シクロペンテンジオールモノアセテート誘導体
KR20110053434A (ko) * 2008-08-19 2011-05-23 유니버시테이트 라이덴 Ａ３ 아데노신 수용체 알로스테릭 조절인자
JP5849044B2 (ja) * 2009-05-17 2016-01-27 キャン−ファイト バイオファーマ リミテッド 眼圧低下のためのａ３アデノシン受容体作動薬
US9549943B2 (en) * 2012-08-09 2017-01-24 Can-Fite Biopharma Ltd. A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
CN103992310B (zh) * 2013-05-14 2016-07-06 中国医学科学院医药生物技术研究所 一组取代苯并杂环胺衍生物及其制备方法和作为impdh抑制剂的相关应用
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
AU2017252640A1 (en) * 2016-04-19 2018-12-06 Innate Tumor Immunity, Inc. NLRP3 modulators
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina Adenosine a3 receptor ligand for use in lowering adipocyte levels
WO2023192408A1 (en) * 2022-03-29 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor positive allosteric modulators
KR20240008807A (ko) * 2022-07-12 2024-01-19 주식회사 넥스트젠바이오사이언스 Hif-1 단백질 억제제로서의 신규한 퓨린 유도체 화합물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960007566A (ko) 1994-08-19 1996-03-22 김정규 신규한 퀴놀릴아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도
CN1195788C (zh) 1997-10-03 2005-04-06 麦克罗梅德公司 具有可逆热胶凝性质的可生物降解低分子量三嵌段聚(丙交酯－共聚－乙交酯)聚乙二醇共聚物
CA2437437A1 (en) * 2001-02-05 2002-08-15 Yasuhisa Kurogi Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, pharmaceutical, composition adenosine a3 receptor affinitive agent, intraocular-pressure reducing agent, pharmaceutical preparation for prevention and treatment of glaucoma, and intraocular-pressure reducing method
US20020179549A1 (en) 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
AU2003274648A1 (en) 2002-10-22 2004-05-13 Can-Fite Biopharma Ltd. The use of the a3 adenosine receptor as a marker for a diseased state
JP2007517019A (ja) 2003-12-29 2007-06-28 カン−フィテ・バイオファーマ・リミテッド 多発性硬化症の治療方法
CN101083998A (zh) 2004-11-22 2007-12-05 王者制药研究发展有限公司 用腺苷a3受体激动剂强化治疗hif－1介导的病症
DK1983990T3 (da) 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer

Also Published As

Publication number Publication date
CN101410114A (zh) 2009-04-15
JP2013253108A (ja) 2013-12-19
CN101410114B (zh) 2012-07-04
EP1983990B1 (en) 2011-03-23
US20130197025A1 (en) 2013-08-01
US9326978B2 (en) 2016-05-03
US20090054476A1 (en) 2009-02-26
JP5414277B2 (ja) 2014-02-12
KR101383228B1 (ko) 2014-04-09
ATE502640T1 (de) 2011-04-15
ES2360632T3 (es) 2011-06-07
JP2009524668A (ja) 2009-07-02
WO2007089507A1 (en) 2007-08-09
EP1983990A1 (en) 2008-10-29
DE602007013359D1 (de) 2011-05-05
US8420664B2 (en) 2013-04-16
KR20080099855A (ko) 2008-11-13

Similar Documents

Publication Publication Date Title
DK1983990T3 (da) Allosteriske A3-adenosin-receptormodulatorer
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
BRPI0517263A (pt) novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
HN2010002774A (es) DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL-CoA
UA94600C2 (en) Indole sulfonamide modulators of progesterone receptors
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
BR0110767A (pt) Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
AR047928A1 (es) Derivados de tetrahidropiridoindol
BRPI0513677B8 (pt) derivados de pirrol como agentes farmacêuticos
ZA200801732B (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
WO2006050058A3 (en) Methods of detection and therapy of inflamed tissues using immune modulation
EA201071288A1 (ru) Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
BRPI0514735B8 (pt) derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina.
BRPI0510126A (pt) derivados de piperidina como moduladores do receptor de quimiocina ccr5
BRPI0517259A (pt) novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
WO2008118141A3 (en) Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
BR0214140A (pt) Derivados de piperidina e sua utilização como moduladores da atividade de receptor de quimiocina (especialmente ccr5)
UY28974A1 (es) Derivados heterocíclicos de piperidina, composiciones que los contienen y procedimiento de preparación
NO20073702L (no) Ikke-steroid glukocorticoid reseptor modulatorer